Loading clinical trials...
Loading clinical trials...
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder
Conditions
Interventions
SHP465
Locations
48
United States
Harmonex Neuroscience Research
Dothan, Alabama, United States
PEWMD, PA, ARCSM, PLLC, PRP, Inc.
Little Rock, Arkansas, United States
Advanced Research Center
Anaheim, California, United States
Riverside Medical Clinic
Riverside, California, United States
Peninsula Research Associates - CRN
Rolling Hills, California, United States
Pediatric Medical Associates
Sacramento, California, United States
Start Date
January 2, 2018
Primary Completion Date
January 19, 2019
Completion Date
January 19, 2019
Last Updated
June 3, 2021
NCT07189442
NCT07180758
NCT07459699
NCT07165509
NCT07121621
NCT06170996
Lead Sponsor
Shire
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions